Dual antiretroviral regimen maintains durable HIV suppression after switch
Four days on, three days off HIV treatment controls viral load in French pilot study
Darunavir/ritonavir & lamivudine matches triple-drug therapy
Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment
Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART
Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?
Week-on, weekend-off treatment controls viral load in young people
Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation
